Steve is currently Executive Director, Process and Analytical Development at Sage Therapeutics and oversees API process development, drug substance and drug product analytical development and CMC leadership for Sage’s later stage portfolio including Zulresso (approved for treatment of post-partum depression or PPD), zuranolone (in phase 3 trials major depressive disorder and PPD) and SAGE-324 (in phase 2 trials for essential tremor).
Before joining Sage, Steve worked at the CDMO Johnson Matthey Pharma Services as Director of R&D and Manufacturing and then Director of R&D and New Technologies. Prior to that, Steve was General Manager and Director of R&D at Codexis Laboratories Singapore (focusing on enzyme directed evolution and biocatalytic process development for the pharmaceutical industry) and spent several years at AMRI (now Curia) at both the Albany, NY and Singapore sites, and at Ultrafine in the UK.
He holds a BSc in Chemistry with Industrial Chemistry and a Ph.D. in Organic Chemistry, both from the University of Liverpool in the UK.
- Primary/Complementary Interactive Styles: Mastermind/Romantic
- Interactive Combination: The Social Reformer
- In a film, he’d be played by: Peter O’Toole
- Common Leadership Characteristic: An agent for change, especially to benefit people
